### ANIMAL CARE COMMITTEE MEETING MINUTES FEBRUARY 16, 2021

Attendees: Member 6, Member 8, Member 9, Member 10, Member 11, Member 30, Member 42, Member 43, and Member 45

Absent: None

Guest: None

- 1. Minutes
- 2. Announcements
- 3. Old Business

### a. Facility Inspection Update

Members 6 and 9 updated the committee on issue raised in November 2020 semi-programmatic review regarding the potential exposure to isoflurane waste gas from bench top vaporizers in investigator labs using nose cones and passive scavenging and that EHSO has started the assessment of waste gas exposure and working with veterinarians to develop guidelines to minimize waste gas exposure of staff to isoflurane.

# 4. Director's Legislative and Facility Update

Member 6 directed the Committee's attention to the report and updated the Committee on the following: 1) That will undergo a 3-hour, weather permitting, scheduled power outage on Saturday, February 27<sup>th</sup>, between 4 and 7 am. This outage will be part of an electrical survey to replace the building's 50 year old electric switch gear and additional outages will be scheduled in the summer as the building's electric switch gear is replaced, 2) that Vice Chancellor for Research (VCR), and FM are in the process of resubmitting last year's C6 grant to replace the will be starting the annual electrical systems, reheat coils and pneumatic control system, 3) that will be starting the annual health assessment in conjunction with UHS for husbandry and research staff that have significant animal contact and 4) That AAALAC Council has completed the review of the UIC Animal Care and Use Program and accepted UIC's responses to the exit interview concerns raised by the site visit team and that as a result UIC will receive continued full accreditation and that the accreditation letter should be expected in the first half of March.

## 5. OACIB Update

### a. Modifications

- 1 -

Member 9 updated the Committee to the following activity during the past month: there were 10 modifications approved at the administrative level, 63 modifications approved administratively following veterinary consult, and 7 modifications approved via designated review this month. In

addition, there were 6 protocols that added personnel, 0 with personnel deletions, 4 that added new funding, and 0 in which animals were added to the holding protocol.

### b. Continuations and Terminations

Member 9 directed the Committee's attention to the protocols for continuation and those terminated due to expiration or PI's request. The Committee discussed that all protocols had completed the appropriate continuation documents and a motion for designated member review for renewal of the protocols was passed by the following vote: 9 in favor, 0 opposed, 0 abstention, and 0 recusals.

### 6. Review from Subcommittee #1



- 5 -

### 21-009

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that clarifications are needed to secure approval with designated member review following full committee review for this protocol was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

### **Clarifications:**

- a. In Form A, item 8g, under study overview, please change to pole and collar method for restraint the hand caught method is no longer used as method of restraint.
- b. In Form A, item 8f, please check "No".
- c. In Form A, item 14, personnel must update ACC Regulatory Training by updating online course "Animals and Research at UIC". **Training must be within three years of the date of review and completed prior to protocol approval**.

### 21-014

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that significant clarifications are needed prior to rereview by

the full committee and to defer this protocol was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

### **Clarifications:**

- a. In Form A, item 6a, please uncheck the Exemption since the telemetry device is digital, there is no need for single housing of animals.
- b. In Form A, item 8a, please provide a brief description of the project in layperson language. Majority of information provided in this section can be moved to 8b.
- c. In Form A, item 8e, please delete bipedal, monkeys are NOT bipedal. Better justification for use of NHPs is needed since other large animals (sheep, pigs) have circadian rhythms and are easier to handle.
- d. In Form A, item 8g, please address the following:
  - i. A lot of discrepancy in what is written in description compared to what is in tables regarding time points. It makes it very difficult to follow. Committee suggests that the written description should only be used to describe the procedures and table should include the specific study design and timelines.
  - ii. Please describe the 4 different implants that will be used. Are they different types of implants or same one being implanted 4 times/site?
  - iii. Please clarify why only males are used in some studies.
  - iv. Please provide clarify what kind of cells will be put in the implant devices. The source of these cells.
  - v. Please describe the peptides and clarify where these peptides will be obtained from and if there are nonpharmaceutical, they should be added to Form A, item 7d2.
  - vi. Please clarify why in Phase 1, study 3a, Endotoxin/Bacteriology (Pre-transplant) is required?
  - vii. Under "Telemetry Placement", please provide separate description for SQ device placement.
  - viii. Procedure C, "Pancreatectomy and NHP islet isolation (Approx. 1.5 hours)", should be removed from this section and listed under necropsy.
    - ix. In Phase 1 study, please clarify how many animals survive to 30 vs 60 days.
- e. In Form A, item 13a, please justify pancreatectomy.
- f. In Form B, item 6c, for all surgeries, methods for monitoring anesthesia depth needs to be provided.





- 17 -



## g. Spring Semi-annual Inspection reminder and dates

Member 9 reminded the Committee of the upcoming dates for semi-annual inspections

### ANIMAL CARE COMMITTEE MEETING MINUTES March 16, 2021

Attendees: Member 6, Member 8, Member 9, Member 10, Member 11, Member 30, Member 43, and Member 45

Absent: Member 42,

Guest: Member 41

### 1. Minutes


### 2. Announcements

Member 9 introduced the new staff of IACUC office to the committee.

### 3. Old Business

-

- 7 -



### 21-035

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that clarifications are needed to secure approval with designated member review following full committee review for this protocol was passed by the following vote: 8 in favor, 0 opposed, 0 abstentions, and 0 recusals.

### **Clarification**:


- a. In Form A, item 8b, please add statement regarding the impact of heart failure on the human population.
- b. In Form A, item 8g, please address the following concerns:
  - i. First paragraph, under gene delivery, please address the following:
    - 1. Please clarify if both carotids and jugulars cannulated? Will they be tied off? There could be potential for issues if all ligated at the same time.
    - 2. Please define RV.
  - ii. Under phase 1, please address the following concerns:
    - 1. Please describe procedure, size of needle/device used for transseptal puncture.
    - 2. In Dose regimen table please clarify what is X and is1, 3, and 10 mg of shRNA?
  - iii. Under Phase 2, please address the following concerns:
    - 1. Acclimation period: Note to PI: Depending as to where PI acquire the animals, longer acclimation period might be necessary (e.g., If hounds are acquired from will, will

### require more than 3 days of acclimation. These dogs are not acclimated by the supplier, so need much more time than beagles from

- 2. Please explain how animals undergo cardioversion to sinus rhythm.
- 3. Under "AERP, VERP and Atrial Fibrillation Inducibility Procedures" please clarify if animals show any reactions to these pacing sessions. Is there any sign of discomfort?
- iv. In Form A, items 8a, 8b, and 8e, PI states that one of the models that are being studied is a Heart failure model (HF), yet under humane end points PI indicates that "Although unlikely, heart failure may be a possible outcome of this experiment". PI should reword these sections (items 8a, 8b, and 8e) if the dogs will not be in heart failure with its associated clinical signs.
- v. Please include sentence that indicates that animals are always observed, while in the restrainer.
- vi. Please include a statement as what will be done if external wires fail to function.
- b. In Form A, item 8h, phase 2 Aim 2, please change 18 dogs to 24 dogs to make total of 48 dogs.
- c. In Form A, item 13a, please address the following concerns:
  - i. Please provide justification as to why thoracic incisions are required to implant Pacemaker leads and why less invasive methods such as placement via the jugular/carotid cannot be used as an alternative model.
  - ii. Please remove the following statement "this procedure is not expected to cause pain or distress" vessel cutdowns for placement of catheters, are surgery and considered painful.
- d. In Form A, item 13b, please address the following concerns:
  - i. Please delete "dog" from search terms.
  - ii. Please redo the lit search for thoracotomy as there are alternatives to thoracotomy to place pacemaker leads.
- e. In Form B, item 4d, please change the dose of Fentanyl Patch to 50-75mcg.
- f. In Form A, item 6b, please address the following concerns:
  - i. Please delete atropine as is not used routinely.
  - ii. Please delete the word "maybe" regarding intubation, the dogs will be intubated for maintaining anesthesia.
  - iii. Please delete last paragraph regarding Echo's since it is not surgery.
- g. In Form B, item 6c please address the following concerns:
  - i. Under surgery # 1, please address the following concerns:
    - 1. Under "External wire placement" please address the following:
      - i. Please change toe pinch to jaw tone.
      - ii. Please add pulse oximetry and capnography for additional monitoring.
    - 2. Under "Plunge and Ball Electrode Placement", please address the following:
      - i. Please clarify what aspect? Ventral? Dorsal? For placement of chest tube.
      - ii. Under step #6, Please add Fentanyl Patch.
  - ii. Under surgery # 2, please address the following concerns:
    - 1. Please change toe pinch to jaw tone.

- 2. Please add pulse oximetry and capnography for additional monitoring.
- 3. Under steps, 2, 3 and 5, please address the following:
  - i. Percutaneously approach is stated for placement of introducer sheath but in Form A, item 8g, states cutdowns, please clarify the approach.
    - ii. It is indicated cut-down into a jugular vein as well as a femoral artery and vein but in Form A, item 8g states carotid as well as jugular. Please also clarify whether unilateral or bilateral approach will be used.
- h. In Form B, item 6f1, please change the dose of Fentanyl Patch to 50-75mcg.
- i. In Form B, item 8, Please include sentence that indicates that animals are always observed, while in the restrainer.

### 8. Review from Subcommittee #3



Uploaded to Animal Research Laboratory Overview (ARLO) on 08/22/2022

Obtained by Rise for Animals.



## **B.** Exemptions

Member 6 indicated that there were two continuations for exemptions requested this month. The Committee discussed the continuations and that they were appropriate and a motion to continue was passed by the following vote: 8 in favor, 0 opposed, 0 abstentions, and 0 recusals

**20-047 Developing a SMART Scaffold for Bladder Augmentation** – The PI of this protocol has requested partial exemption from the UIC Environmental Enrichment Plan. More specifically, the PI has requested exemption from social contact through pair or group housing while the urinary catheter is in place post bladder augmentation surgery. Animals will be returned to their previous social housing once the catheter is removed.

## C. Lab Visits

The following labs/investigators were visited during the last month:

Location	Protocol(s)
	20-068 20-126, 19-215 18-204, 19-192, 20-115
10. New Business	
	- 19 -



## c. Spring Semi-annual Inspection reminder and dates

Member 9 reminded the Committee of the upcoming dates for semi-annual inspections.

## ANIMAL CARE COMMITTEE MEETING MINUTES April 20, 2021

Attendees: Member 6, Member 8, Member 9, Member 10, Member 11, Member 30, Member 42, Member 43, and Member 45

Absent: N/A

Guest: Member 41

- 1. Minutes
- 2. Announcements

None

3. Old Business



- 4 -

- 5 -

- 7 -




## 21-014

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that significant clarifications are needed prior to rereview by the full committee and to defer this protocol was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

## **Clarifications:**

Note: The subcommittee has requested to meet with PI to discuss the project and committee's concerns prior to submission of next set of the clarification, since most clarification from last review were not fully addressed and there are significant concerns regarding this project.

8. Review from Subcommittee #3





## **B.** Exemptions

Member 6 indicated that there was one continuation for exemptions requested this month. The Committee discussed the continuations and that they were appropriate and a motion to continue was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals

**20-070:** The PI of this protocol has requested partial exemption from the UIC Environmental Enrichment Plan. More specifically, the PI has requested:

1) Animals be temporarily exempt from social housing (contact and mesh) during MPTP treatment. Individual animals may respond differently to MPTP resulting in differing levels of neurological impairment that may put them at risk for injury in a social housing paradigm. To prevent such injury, animals have always been housed individually during MPTP administration until stable PD is established. Animals will always be housed in a room with other NHPs and will have visual, olfactory, and vocal contact with other animals.

2) Animals be temporarily exempt from social housing (contact and mesh) during SPECT radioactive isolation housing. They will be kept separate during the decay period (10 half-lives) so that urine in the excrement pans can be monitored via Geiger counter for any radioactivity present prior to removal from isolation. Animals will always be housed in a room with other NHPs and will have visual, olfactory, and vocal contact with other animals.

3) Once an animal has been selected to participate in a study involving functional assessment by hand reach task (HRT), these animals will be permanently exempt from social housing (contact and mesh) beginning with baseline behavioral HRT data collection. An injury to the arm, hand, or fingers can

- 17 -

severely affect the HRT results. Animals will always be housed in a room with other NHPs and will have visual, olfactory, and vocal contact with other animals.

## C. Lab Visits


The following labs/investigators were visited during the last month:



19,175 20-135 18-110, 19-210 18-136, 20-241 18-171, 18-194, 19-026, 19-085 18-132, 20-101

18-076, 18-235, 19-002, 19-041, 19-160,

10. New Business



## d. Spring Semi-annual Inspection Update

Member 9 reminded the Committee that the Facility and Programmatic Review is scheduled on May 12<sup>th</sup> at 2 PM.

## ANIMAL CARE COMMITTEE MEETING MINUTES May 18, 2021

Attendees: Member 6, Member 8, Member 9, Member 10, Member 11, Member 30, Member 42, Member 43, and Member 45

Absent: N/A

Guest: Member 41

## 1. Minutes

The Committee discussed December 2020 minutes and a motion to approve the minutes was passed by the following vote: 9 in favor, 0 opposed, 0 abstention, and 0 recusals.

## 2. Announcements

None

3. Old Business

None

## 4. Director's Legislative and Facility Update

Member 6 directed the Committee's attention to the report and updated the Committee on the following: 1) that number of candidates applied for the open clinical veterinary position; however, few have dropped out from consideration as they have found jobs, and that first round of Zoom interviews have been conducted with the remaining candidates and the next step would be, to have an onsite interview with the candidates within the next two weeks and that 2) The C06 grant that was submitted to renovate/replace key HVAC and electrical infrastructure in the **scheduled** for review by June 23<sup>rd</sup> with priority scores and summary statements available by July 18<sup>th</sup>. Funding based upon priority scores will be available between August and October.

## 5. OACIB Update

## a. Modifications

Member 9 updated the Committee to the following activity during the past month: there were 10 modifications approved at the administrative level, 60 modifications approved administratively following veterinary consult, and 7 modifications approved via designated review this month. In addition, there were 4 protocols that added personnel, 0 with personnel deletions, 3 that added new funding.

## b. Continuations and Terminations

Member 9 directed the Committee's attention to the protocols for continuation and those terminated due to expiration or PI's request. The Committee discussed that all protocols had completed the appropriate continuation documents and a motion for designated member review for renewal of the protocols was passed by the following vote: 9 in favor, 0 opposed, 0 abstention, and 0 recusals.

## 6. Review from Subcommittee #1

Uploaded to Animal Research Laboratory Overview (ARLO) on 08/22/2022

Obtained by Rise for Animals.



## 21-058

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that clarifications are needed to secure approval with designated member review following full committee review for this protocol was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

## **Clarifications:**

- a. In Form A, item 5c2 and 5c3, please change OR to procedure room.
- b. In Form A, item5c2, please clarify what surgery will be performed at
- c. In Form A, item 6c, please check "yes" for single housing in case of infection, wound management requires bandage which could be disrupted by a cage mate.
- d. In Form A, item 8g, please address the following:
  - i. Under A, Anesthesia.
    - 1. Please change midazolam to acepromazine 0.05 mg/kg SQ.
    - 2. Delete b2 and b3 and the following "\*\*Option 1 is the default option. Only one option will be used at a time. The other options are present in case of extenuating circumstance. Medication is administered by technicians."
    - 3. Please remove item e, regarding urinary Catheters
  - ii. Under F, Post-procedural complications, please add "such as infection" to procedural complication.
  - iii. Please clarify how many mapping procedures will be done per animal within each project?
  - iv. Please remove the Quality control statement.
- e. In Form A, item 4d, please change "once daily" to "SQ". Also change the dose of Cephalexin to 30 mg/kg.
- f. In Form B, item 6c, please provide the following information for all the surgeries: 1) the methods used to monitor the state/depth of anesthesia, 2) the approximate size and location of incision(s), 4) the approximate duration of the procedure, 6) the timing of initial dose of analgesic.
- g. In Form B, item 6f1, please change Meloxicam to Meloxicam SR and duration should say lasts for 3 days and delete the last two rows.
- h. In Form B, item 9, please describe the procedure and provide justification. Also remove the statement regarding-adjustment of medications.



## 21-070

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that clarifications are needed to secure approval with designated member review following full committee review for this protocol was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

## **Clarifications:**

- a. Note to PI: There are no animals in house to serve as blood donors for this study as was done in the past, therefore PI needs to blood match his animals at the time of purchasing experimental animals so they can serve as blood donors for each other.
- b. In Form A, item 2b, please change to "1" for role on the protocol.
- c. In Form A, item 6a, please remove the request for Exemption since these animals will not be immunosuppressed.
- d. In Form A, item 8a, 2<sup>nd</sup> paragraph, please remove the description of In-vitro cell manipulation and add the purpose of the study and how does this part impact human health, using lay language.
- e. In Form A, under item 8g, please address the following:
  - i. Under study A:
    - 1. Under preoperative regimen, please indicate the frequency of Ondansetron treatment, is it every time prior to Busulfan administration? Please clarify.
    - 2. Please clarify what happens to the animals at the end of the study, PI indicates that animals from Study B, will not be euthanized, would it be the same for animals in Study A, please clarify.
  - ii. Under Study B:
    - 1. Please change "using standard protocol for IV transfusion and sedation" to "via IV catheter placed in the saphenous or cephalic vein".
    - 2. Under Sampling, please address the following:

- a) Please delete xylazine, just ketamine will be enough.
- b) Please clarify if the procedure to co-transfuse autologous and control or ADAMTS13expressing cultured RBCs labeled with PKH26in two cohorts of baboon (n = 3/cohort) is the same procedure as listed on the above paragraph.
- f. In Form A, item 14, the following personnel must complete or update ACC Regulatory Training by updating online course "Animals and Research at UIC": Personnel 1. Please see attached instructions. Training must be updated every 3 years and completed prior to protocol approval
- g. In Form B, item b7, please add Busulfan administration of adverse side effects.
  - 8. Review from Subcommittee #3

- 15 -

# **B.** Exemptions

None

# C. Lab Visits

The following labs/investigators were visited during the last month:




20-131 20-032 20-142 18-156, 21-031

### 10. New Business

### a. Semi-Annual Programmatic and Inspections

Member 2 directed the Committee's attention to the Programmatic Review Report. The Committee noted that there were no significant deficiencies noted. The Committee noted the following corrections were needed: the review of the bench type isoflurane vaporizers that use passive scavenging in order to assess potential staff exposure to waste gases, need to identify a mechanism to include FM staff on an individual basis in the occupational health program or to provide them with the opportunity to take part in the OCC health program, need to update the SOP for hypoxia chamber room in order to address oxygen sensor replacement, and PI to develop an SOP on the maintenance of the zebra fish colony. The SOP should be in accordance with the UIC ACC policy on zebra fish. Member 2 directed the Committee's attention to the veterinary review and that there were no deficiencies noted. The Committee reviewed and approved the report of departures and the report on primate enrichment program. Following discussion, Member 9 requested that committee members send in email confirmation for approving the report in lieu of their signature due to nature of the meeting (Zoom meeting) and there were no minority reports.

Member 10 directed the Committee's attention to the Semi-Annual Inspection Report. The Committee discussed that there were no significant deficiencies and reviewed the plan of action to correct the minor deficiencies. Following discussion, Member 9 requested that committee members send in email confirmation for approving the report in lieu of their signature due to nature of the meeting (Zoom meeting) and there were no minority reports.





# f. Q Fever Guidelines

The Committee reviewed the guideline and discussed that there were only minor editorial changes required to this guideline. Following review, a motion to approve the policy was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

### ANIMAL CARE COMMITTEE MEETING MINUTES JUNE 15, 2021

Attendees: Member 6, Member 8, Member 9, Member 10, Member 11, Member 30, Member 43, Member 45, and Member 48

Absent: Member 42

Guest: Member 41

### 1. Minutes

The Committee discussed January 2021 minutes and a motion to approve the minutes was passed by the following vote: 8 in favor, 0 opposed, 1 abstention, and 0 recusals.

### 2. Announcements

### None

# 3. Old Business

# 4. Director's Legislative and Facility Update

Member 6 directed the Committee's attention to the report and updated the Committee on the following: 1) that search for the open clinical veterinary position has failed and in the meantime, it was the consensus of the senior veterinary staff to make things work with current staffing level with the intent to fill the position next summer, that 2) There had been some maintenance issues with the cooling tower resulting in warmer than expected during the warmer weather experienced in June and that it is temperatures in the important to resolve the issues now before potentially warmer days of July and August are here, that 3) the veterinary staff have developed two different slide sets addressing Laboratory Animal Allergens and potential risks of working in an animal facility which will be targeted for lab staff with direct and indirect animal exposure and FM staff and will be incorporated into the general lab safety training module (research staff) and the annual hazardous communication training module (FM staff) offered through EHSO. These training modules will ensure that research staff and FM staff are aware of the hazards of working around animals and address a concern raised by the site visit team during our last AAALAC site visit. We are now looking to develop an informative brochure for visitors to the and other animal facilities on campus, and that 4) the veterinary staff are in the process of working with EHSO to examine Waste Anesthetic Gas Exposure (WAGs) as requested by AAALAC and to date two of four scavenging system types have been tested. Upon completing the assessment and analyzing the data Vet staff will make recommendations to the research community regarding the use of isoflurane anesthetic machines and scavenging and update appropriate policies. It should be noted that vet staff have developed an anesthetic delivery system check list for PIs to guide them on how to make sure their equipment is working properly thus minimizing WAG exposure.

# 5. OACIB Update

## a. Modifications

Member 9 updated the Committee to the following activity during the past month: there were 15 modifications approved at the administrative level, 52 modifications approved administratively following veterinary consult, and 6 modifications approved via designated review this month. In addition, there were 4 protocols that added personnel, 0 with personnel deletions, 3 that added new funding.

### b. Continuations and Terminations

Member 9 directed the Committee's attention to the protocols for continuation and those terminated due to expiration or PI's request. The Committee discussed that all protocols had completed the appropriate continuation documents and a motion for designated member review for renewal of the protocols was passed by the following vote: 9 in favor, 0 opposed, 0 abstention, and 0 recusals.

### 6. Review from Subcommittee #1

- 7 -

d

е



# 21-014

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that significant clarifications are needed prior to rereview by the full committee and to defer this protocol was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

# **Clarifications:**

- a. In Form A, Item 5c1, please add the "implantation of a single device" in the list of procedures to be performed in this location.
- b. In Form A, Item 8b, please address the following:
  - i. Please explain what peripheral and central clocks are?
  - ii. Last Paragraph, last sentence starting with "We have elected NHP..." to item 8e.
- c. In Form A, Item 8g, please address the following:
  - i. What material constitutes the carrier device?

- 13 -

- ii. Under A, 4<sup>th</sup> sentence, please remove the specific size of suture will be used for muscle or skin.
- iii. Under B, please address the following:
  - 1. Please add the following parameters in addition to checking the vitals, checking oxygen saturation, blood pressure, capnography, and body temperature.
  - 2. Please replace pinch reflex with jaw tone and palpebral reflex.
  - 3. Please clarify the anatomic location (for example the implants will be placed IM, SC, IP or subP) for all the implants rather than just "muscular".
  - 4. Please clarify if the contract surgeon, will perform all the surgeries or the PI and staff will get trained to perform surgeries.

- 5. PI should consult with technical team regarding the placement of telemetry devices particular to this project and adjust the surgery protocol writeup specific to this project rather than just attaching the surgical manual.
- iv. Under D, the frequency of blood draws and body weight measurements indicated in this section does not match what is indicated in study design tables, the text implies much greater frequency, please reconcile.
- v. Under E, please delete the anesthetic regimen. Anesthesia described blood collection and should be ketamine 10 mg/kg. Please indicate vet staff or vet techs will collect urine samples.
- vi. Study design tables:
  - 1. Table I, please indicate 12 devices total/animal.
  - 2. Table II, please indicate the study end date (Necropsy time) as we agreed these animals should be euthanized and new group of animals will be used for part III.
  - 3. Under study IIIa and IIIb, please address the following:
    - a. Study IIIa, please describe the activation process of the cells and clarify how long are the cells activated for.
    - b. Table for IIIa, please indicate 12 devices total/animal.
  - 4. Study IV, please change harness or compression strap to jacket or collar.
  - 5. Under optogenetic control, please clarify/explain how long is this device on? Constantly? X number of hours per day for X number of days?
  - 6. Under study IIIb, please clarify what is sub-peritoneal site since prior sites were SQ abdominal. Why wasn't this site tested previously? Why is this site added here?
  - 7. Under study IIIb, please clarify how long after the light cycle is adjusted is the device turned on?
  - 8. Duration of Entrainment studies are not the same between text and what is presented in the tables, please reconcile.
  - 9. Under study IIIb, please clarify how long is the observation period before adjustments are made, and what adjustments would be made? Activation for longer time-period? Activation for the same time-period but for multiple days in a row?
  - 10. Possibility of immune response to cells in carrier device, or are they sufficiently protected from surrounding tissue?
  - 11. Are cells genetically modified? Peptides/optogenetic sensor?
- d. In Form A, Item 8h, this power calculation should be on the device level, not animal level. If they're putting 12 devices in each animal, they don't need 4 animals.
- e. In Form A, item 13a, please justify telemetry device implantation
- f. In Form A, item 13b, please conduct search for alternatives to telemetry device implantation.
- g. Form B, Item 6c, surgery # 2, please clarify the location where telemetry device with implanted in the abdominal cavity. Also, indicate meloxicam SR will be given preop and bup SR will be given postop along with bupivacaine at incision sites.

- 15 -

# **B.** Exemptions

### None

# C. Lab Visits

The following labs/investigators were visited during the last month:



**10. New Business** 

# a. Semi-Annual Programmatic and Inspections

20-153 20-069

19-138

18-218, 19-055

Member 2 directed the Committee's attention to the Programmatic Review Report. The Committee noted that there were no significant deficiencies noted. The Committee noted the following corrections were needed: the review of the bench type isoflurane vaporizers that use passive scavenging in order to assess potential staff exposure to waste gases, need to identify a mechanism to include FM staff on an individual basis in the occupational health program or to provide them with the opportunity to take part in the OCC health program, need to update the SOP for hypoxia chamber room in order to address oxygen sensor replacement, and PI to develop an SOP on the maintenance of the zebra fish colony. The SOP should be in accordance with the UIC ACC policy on zebra fish. Member 2 directed the Committee's attention to the veterinary review and that there were no deficiencies noted. The Committee reviewed and approved the report of departures and the report on primate enrichment program. Following discussion, Member 9 requested that committee members send in email confirmation for approving the report in lieu of their signature due to nature of the meeting (Zoom meeting) and there were no minority reports.

- 21 -

Member 10 directed the Committee's attention to the Semi-Annual Inspection Report. The Committee discussed that there were no significant deficiencies and reviewed the plan of action to correct the minor deficiencies. Following discussion, Member 9 requested that committee members send in email confirmation for approving the report in lieu of their signature due to nature of the meeting (Zoom meeting) and there were no minority reports.

# f. Q Fever Guidelines Update

The Committee reviewed the guideline and discussed that the minor editorial changes required to this guideline were completed and that no additional clarifications were required. Following discussion, a motion to approve the policy was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

## ANIMAL CARE COMMITTEE MEETING MINUTES July 20, 2021

Attendees: Member 6, Member 8, Member 9, Member 10, Member 11, Member 30, Member 41, Member 42, Member 45, and Member 48

Absent: Member 43

## **Guest:**

## 1. Minutes

The Committee discussed February 2021 minutes and a motion to approve the minutes was passed by the following vote: 8 in favor, 0 opposed, 2 abstention, and 0 recusals.

### 2. Announcements

None

# 3. Old Business

# a. ACC Protocol 21-014:

The Committee reviewed the revised protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that clarifications are needed to secure approval with designated member review following full committee review for this protocol was passed by the following vote: 10 in favor, 0 opposed, 0 abstentions, and 0 recusals.

# **Clarifications:**

- a. In Form A, Item5c, please in SQ implants (up to 4) can be inserted in the primate procedure room in
- b. In Form A, Item 14, please remove reference to Telemetry device implantation
- c. In Form B, Item 4, please add xylazine IM 1 mg/kg.
- d. In Form B, Item B6a, this description is for laparoscopic surgery. Change to shave and scrub lower abdomen, dorsum, and upper arm.
- e. In Form B, Item 6b, please clarify that anesthesia will differ based on # of implants. For 12 implants, PI will use ketamine sedation, propofol induction, and isoflurane maintenance. For 1-4 implants, PI will use ketamine/xylazine. Delete xylazine from the first sentence.
- f. In Form B, Item 6c, please change time frame 30-90 minutes.
- g. In Form B, Item 6f, please delete meloxicam SR from list. It's given pre-op.




- 2 -

- 3 -








- 11 -

- 13 -

- 14 -



# 6. Review from Subcommittee #2

# 21-093

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that clarifications are needed to secure approval with


designated member review following full committee review for this protocol was passed by the following vote: 10 in favor, 0 opposed, 0 abstentions, and 0 recusals.

# **Clarifications:**

- a. In Form A, Item 4, please indicate 5 animals are being transferred form PI protocol #(18-125) and 3 animals are new animals that will be transferred from PI's holding protocol.
- b. In Form A, item 8c, please indicate which experimental group these 3 animals will belong based on the studies approved under 18-125 in addition to where the remaining five animals are.
- c. In Form A, Item 8g, please address the following:
  - i. Please provide study design table and indicate the experimental groups these 8 animals belong.
  - ii. Under Levodopa/Carbidopa dosing, please remove the following sentence: *"This dose range is chosen based on previous reports by our colleagues at*"
- d. In Form A, Item 8h, please remove justification of N=8, because these 8 animals all are not part of the same group and PI can provide an explanation that these 8 animals will be part of the original study with N=6 and they belong to what experimental groups based on what was approved under 18-125
- e. In Form B, Item 9, please provide justification for PD induction.

# 7. Review from Subcommittee #3

# 8. Designated Review(s), Exemptions, and Lab Visits



# **B.** Exemptions

None

# C. Lab Visits

The following labs/investigators were visited during the last month:




18-130, 19-018 20-221, 20-222 19-052, 20-064, 20-168, 20-180 19-123, 20-191

## 9. New Business



- 18 -



## d. Guideline 321: Survival Surgery in Rodents and Lower Vertebrates (Version 4.1)

The Committee reviewed the revised guideline and discussed that the minor editorial changes required to this guideline were completed and that no additional clarifications were required. Following discussion, a motion to approve the guideline was passed by the following vote: 10 in favor, 0 opposed, 0 abstentions, and 0 recusals

## ANIMAL CARE COMMITTEE MEETING MINUTES August 17, 2021

Attendees: Member 6, Member 9, Member 10, Member 11, Member 30, Member 41, Member 42,

Member 45, and Member 48

Absent: Member 8 and Member 43

## **Guest:**

- 1. Minutes None
- 2. Announcements

Committee said farewell to Member 30 and thank them for their service to IACUC for the past 3 years.

# 3. Old Business

## None

# 4. Director's Legislative and Facility Update

Member 6 directed the Committee's attention to the report and updated the Committee on the HVAC renovation project continues to move forward, and Facility personnel following: 1) that will meet with the Project team beginning July 19th to finalize a timeline for the project and that the project could start as September. The first part of the project will begin in the cage wash area after , which will result in for all which the project will move onto the second floor and the roof of the primates to relocated to the basement of the and that this project is estimated to take 18-24 months and will impact all areas of the Once a timeline is finalized staff will be reaching out to UIC users to discuss the project and its potential effect on users, 2) That is in process of interview for supervisor position, and 3) that, the veterinary staff have just implemented a new procedure for visitors entering the **sec**, which includes signing off on a log that they have been informed of the risks of entering an animal facility and next to the log is an informational sheet that provides the visitors of the potential risks and directs them to health care professionals should there be health concerns.

# **OACIB** Update

# a. Modifications

Member 9 updated the Committee to the following activity during the past month: there were 15 modifications approved at the administrative level, 60 modifications approved administratively following veterinary consult, and 6 modifications approved via designated review this month. In addition, there were 7 protocols that added personnel, 0 with personnel deletions, 3 that added new funding.

# b. Continuations and Terminations

Member 9 directed the Committee's attention to the protocols for continuation and those terminated due to expiration or PI's request. The Committee discussed that all protocols had completed the

appropriate continuation documents and a motion for designated member review for renewal of the protocols was passed by the following vote: 9 in favor, 0 opposed, 0 abstention, and 0 recusals.

# 5. Review from Subcommittee #1

- 8 -

- 9 -

- 10 -



# 8. Designated Review(s), Exemptions, and Lab Visits

## A. Protocols

## None

## **B.** Exemptions

Member 6 indicated that there was one continuation for exemptions requested this month. The Committee discussed the continuations and that they were appropriate and a motion to continue was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals

**20-155** - The PI is requesting continuation of his partial exemption from the UIC Environmental Enrichment Program for Nonhuman Primates. More specifically the PI is requesting exemption from introduction of social housing partners (mesh or full contact) for all animals that will be tested with the hand reach task (HRT). During the introduction of new social pairs, it is common for animals to fight, leading to injury and the possibility of a major injury to a hand/arm/digit that would severely impair behavioral analysis of fine motor skills (i.e., HRT), a primary measure of our experimental treatments. Animals will have access to all other aspects of the program.

# C. Lab Visits

The following labs/investigators were visited during the last month:

Location

Protocol(s)



19-011, 19-083, 19-214, 20-214 19-132, 21-011 18-183, 20-005 19-048, 20-074 18-121, 19-100, 20-042, 20-066, 21-010 19-203, 20-239 20-057, 20-060, 20-139

# c. Modification of Protocol 20-040 (17)

The Committee reviewed PI's request to conduct a 48 animal toxicokinetic study for a cerebral endothelin B receptor drug that is currently being used in human clinical trials to improve neurologic outcomes in patients with acute cerebral ischemic stroke. The study involves 3 phases including a maximum tolerated dose study, a 7-day repeat dose study to determine toxicokinetic and a final 28-day GLP study to determine toxicokinetic. It should be noted that the agent administration (IV) and blood collection (saphenous, cephalic, and jugular) routes are consistent with what is in the original protocol as well as the monitoring frequency, monitoring parameters and endpoint criteria. It should also be noted that the drug has been tested in animals before so there is preliminary data to draw on to determine where to start for dosing and no toxicity was noted. Following discussion, a motion that PI will need to provide additional information regarding the re-testing requirement and once the information is obtained from PI, the modification will be reviewed through Designated Review process was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

# ANIMAL CARE COMMITTEE MEETING MINUTES SEPTEMBER 21, 2021

Attendees: Member 6, Member 8, Member 9, Member 10, Member 11, Member 30, Member 42, Member 45, and Member 48

Absent: N/A

Guest: 41

- 1. Minutes
- 2. Announcements
- 3. Old Business

4. Director's Legislative and Facility Update

- 1 -

Member 6 directed the Committee's attention to the report and updated the Committee on the following: 1) UIC has been notified by NIH that grant to upgrade HVAC infrastructure to support ventilated racks which will allow for colony expansion as well as the development of a PDX core and a metabolic disease core has been funded. This project will be done in conjunction with what Facilities has planned as part of the HVAC renovation project. Due to some of the requirements of NIH for C06 grants the timeline previously mentioned for starting the project in mid-October has been pushed back. The new timeline is still under development though some work is expected to begin on November 2) The first week in October the will be sending out animal usage data to USDA covered animal users, which they will complete as part of our retrospective assessment of how animals were used in terms of USDA categories. This information is then used to complete the institution's Annual USDA Report. Two things will be different this year: 1) We are going to use an on-line data entry portal, i.e. the investigators will not have to submit paper or email forms; 2) We are only going to send out the request to USDA animal users, i.e. we will no longer send out notices and require users of mice and rats to complete this form as this is not required by the USDA for those respective species and 3) It appears that Biology Dept is recruiting two investigators one of whom will bring a large colony of mole rats to campus and the other will bring a colony of bats. The animals will be housed in the SES facility and the bat colony will require the establishment of a new satellite. Both investigators are not scheduled to be on campus until December/first of the year.

- 4 -

## Obtained by Rise for Animals.

Uploaded to Animal Research Laboratory Overview (ARLO) on 08/22/2022

- 8 -

- 12 -

### 21-134

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that significant clarifications are needed prior to rereview by the full committee and to defer this protocol was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals

### **Clarifications:**

# Committee's concern: No one has been listed in the protocol that has experience with implantation of telemetry device. The procedure listed in Form B, is for dogs and not NHP.


- a. General Comment, please replace NHP with Cynomolgus monkeys in Form A and Form B.
- b. In Form A, Item 8b, please indicate if any toxicity has been seen with this compound in studies done in mice.
- c. In Form A, Item 8d, please change cardiac safety to cardiac-respiratory safety.
- d. In Form A, Item 8e, please clarify why other non-rodent species other than NHP could not be used for this project. Also justify using only males.
- e. In Form A, Item 8g, please address the following:
  - i. Under acclimation, please remove technician A and B, just indicate 2 technicians.
  - ii. Please clarify if using chemical restraint is option why not just forgo of pole and collar training for this short project.
  - iii. Please clarify what kind of blood work will be performed to allow for 2<sup>nd</sup> and 3<sup>rd</sup> and 4<sup>th</sup> dose to proceed. (During washout period?)
  - iv. Under Clinical pathology, collecting 4-5 ml from a cephalic vein via catheter is very challenging, should use femoral vein.
  - v. End of the Study, returning animal to colony, please clarify which colony?
- f. In Form A, Item 10a, please change the dose to 1 ml per 10 lbs.
- g. In Form A, Item 12a, 2<sup>nd</sup> part should be marked "yes" due to the surgical procedure.
- h. In Form A, Item 13b, please redo the Lit search since there are alternatives to telemetry and restraint. Also, NHP should be used as part of search term.
- i. In Form A, Item 13c, what is describe here is not the painful procedure. PI needs to describe alternatives to surgical implantation of telemetry and explain why they can't be used (or telemetry is better).
- j. In Form A, Item 14, please indicate personnel's experience with pole and collar training.
- k. In Form B, Item 6b and 6c, please address the following:

- i. Meloxicam should be given pre-op, please delete post-op.
- ii. Under Surgery #1, reverse the order, ketamine given first 10 mg/kg IM, and then propofol IV.
- iii. Change the dose of cefazolin to 25 mg/kg.
- iv. Delete the acepromazine treatment.
- v. Change the hydromorphone dose to 0.1-0.2 mg/kg from 0.1-0.02 mg/kg.
- 1. In Form B, Item 8, please indicate ketamine at 10 mg/kg will be used for chemical restrain.
- m. In Form B, Item 9, please indicate what are the procedures causing significant disease?

Uploaded to Animal Research Laboratory Overview (ARLO) on 08/22/2022

Obtained by Rise for Animals.

- 16 -



### **B.** Exemptions

Member 6 indicated that there was one continuation for exemptions requested this month. The Committee discussed the continuations and that they were appropriate and a motion to continue was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals

**20-190 Toxicity and Pharmacokinetics Testing of VT-109 in Non-human Primates -** The PI is requesting continuation of his partial exemption from the UIC Environmental Enrichment Program for Nonhuman Primates. More specifically, animals on study may have tactile (mesh) contact but not full contact social housing. This is required to monitor clinical signs such as vomiting or diarrhea, etc., and food consumption. Before a study and following completion of a study animals may have full contact housing.

### C. Lab Visits

The following labs/investigators were visited during the last month:

Location	Protocol(s)
	21-043
	18-144, 18-239, 19-004, 20-158
	19-032, 19-035, 19-077, 19-161, 20-077,
	20-127, 20-236, 21-059
	19-217, 20-031, 20-099
	19-188, 20-169
	,

### 9. New Business

a. Regulatory Guideline and Policy Updates:

- 20 -

None

### b. Semi-Annual Inspection Dates

Member 9 informed the Committee of the dates for next inspections and asked the members to contact Member 10 as to which portions, they would participate.

### c. Re-instatement of Satellite facility in

The Committee reviewed PI's request for re-instatement of satellite facility. Following discussion, a motion to approve the re-instatement of satellite facility was approved by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.



### ANIMAL CARE COMMITTEE MEETING MINUTES October 19, 2021

Attendees: Member 6, Member 8, Member 9, Member 10, Member 11, Member 30, Member 42, Member 45, and Member 48

Absent: N/A

Guest: 41


### 1. Minutes

June 2021 minutes was approved by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

### 2. Announcements

None

### 3. Old Business



- 5 -

### 21-134

The Committee reviewed the protocol and discussed that the PI needed to address clarifications listed below. Following discussion, a motion that clarifications are needed to secure approval with designated member review following full committee review for this protocol was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.

- 12 -

### **Clarifications:**

- a. In Form A, Item 8e, please expand on the answer for justification of only using males. Also, PI has indicated "We do not expect any major differences between males and females. The comparison will be made between vehicle control group vs. dose groups", this not valid justification for using only males, please provide valid justification.
- b. In Form A, Item 8g, please address the following:
  - i. Under acclimation, still not clear why training animals to pole and collar is necessary for this study, where use of anesthetic agent is proposed for animals that cannot be acclimated to pole and collar.
  - ii. Please clarify how Clinpath data will be used for assessing drug levels to allow for 2<sup>nd</sup> and 3<sup>rd</sup> and 4<sup>th</sup> dose to proceed. (during washout period?)
  - iii. Under body weights: Please clarify why animals need to be weighed daily for duration of study.
  - iv. Under Clinical pathology, please address the following:
    - 1. Please clarify for how many days blood will be collected following each dose, since the protocol indicates each day following dosing.
    - 2. Please remove using catheter to collect blood from femoral vein, since catheter is not used for femoral bleed.
- c. In Form A, Item 13a, please remove the last paragraph, regarding use of analgesics.
- d. In Form A, Item 14, please remove personnel # 7 since not directly involved with animal work.
- e. In Form A, Item 14, still not clear who will be implanting the telemetry device, please clarify. This will need to clear prior to submission of revised protocol.
- f. In Form B, Item 4, please change the dose of bupivacaine to 1 mg/kg.
- g. In Form B, Item 6b, Meloxicam SR should be given pre-op immediately prior to surgery not the day before, please reconcile.
- h. In Form B, Item 6c, please remove the write up regarding the terminal procedure, since this is not part of this study. This must have been cut and paste from another study.
- i. In Form B, Item 8, please answer for prolong restrain (>20 minutes restrain) for use of pole and collar if that will be the method of restrain.
- j. In Form B, Item 9, the humane end point criteria should match between 8g and this section please reconcile

- 16 -



### 8. Designated Review(s), Exemptions, and Lab Visits

A. Protocols

None

### **B.** Exemptions

Member 6 indicated that there was one continuation for exemptions requested this month. The Committee discussed the continuations and that they were appropriate and a motion to continue was passed by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals

**20-205 Efficacy of the novel drug candidate in treating lung inflammation and injury associated with SARS-CoV-2 infection study in NHP** - The PI is requesting continuation of the partial exemption from the UIC Environmental Enrichment Program for Nonhuman Primates. More specifically, animals on this protocol may have full contact social housing when not on study. When animals are entered into the study, they may have sight and tactile (mesh) contact but not full contact social housing. This is required to monitor clinical signs such as vomiting or diarrhea, etc., and food consumption. Observations following virus inoculation and dosing will be a minimum of 3 days and maximum 7 days. Following completion of a study, animals are euthanized for tissue harvest.

The following labs/investigators were visited during the last month:

Location	Protocol(s)
	20-076 20-240 20-082
	20 002

### 9. New Business

### a. Regulatory Guideline and Policy Updates:


### None

### b. Semi-Annual Inspection Dates

Member 9 informed the Committee of the dates for review of facility inspections and programmatic review and asked the members to contact Member 10 as to which portions, they would participate.

### c. Satellite facility in

The Committee reviewed PI's request for re-instatement of satellite facility. Following discussion, a motion to approve the re-instatement of satellite facility was approved by the following vote: 9 in favor, 0 opposed, 0 abstentions, and 0 recusals.



- 19 -